Edition:
United Kingdom

Theratechnologies says FDA sets PDUFA date of Jan 3 for ibalizumab application


Friday, 30 Jun 2017 

June 30 (Reuters) - Theratechnologies Inc ::FDA grants priority review to HIV monoclonal antibody and long-acting investigational antiretroviral ibalizumab.FDA has set a prescription drug user fee act target action date of January 3, 2018, for ibalizumab application. 

Company Quote

5.5
 --
22 May 2019